The class, defined
Recovery peptides are short protein chains studied for their effects on tissue repair — tendons, ligaments, muscle, cartilage, connective tissue, gut lining, and skin. The category is anchored by BPC-157 (body protection compound) and TB-500 (a fragment of thymosin beta-4), which together form the most popular self-experimental peptide stack in the biohacking community. Neither has FDA approval for injury repair. Both have a mixed evidence base — rich preclinical data showing accelerated healing in rat tendon-injury, colitis, and muscle-injury models, but limited human clinical trials. This hub catalogs every recovery peptide PeptaHub profiles — five direct repair peptides plus two cross-category peptides (GHK-Cu from skin, KPV from immune) that are frequently used in recovery protocols. For each compound, we link to the profile page with mechanism, dosing, legal status, and what the clinical literature actually supports.
How they work
Recovery peptides work through several overlapping mechanisms: promoting angiogenesis (new blood-vessel formation) at injury sites, upregulating growth factors (VEGF, FGF, PDGF) that coordinate fibroblast and epithelial repair, modulating inflammation via macrophage polarization from pro-inflammatory M1 to pro-healing M2 phenotypes, and stimulating collagen synthesis by fibroblasts. BPC-157 additionally upregulates growth hormone receptors in tendon fibroblasts — a mechanism that distinguishes it from other repair peptides and explains its particular reputation for tendon and ligament healing. TB-500 (thymosin beta-4) is a G-actin sequestering peptide that also drives cell migration, making it complementary to BPC-157 in the popular 'Wolverine stack' combination.
BPC-157 and GH receptor upregulation
BPC-157 is derived from a 15-amino-acid sequence in human gastric juice. Its best-characterized mechanism is upregulating growth hormone receptors in tendon fibroblasts, potentiating the anabolic effect of endogenous GH on collagen synthesis. Additional effects include activation of the FAK-paxillin pathway (cell migration) and nitric-oxide system modulation (blood-flow and vasoprotection).
TB-500 and G-actin sequestration
Thymosin beta-4 (TB-500 is a synthetic fragment) binds and sequesters G-actin, a process that indirectly promotes cell migration, wound contraction, and vascular endothelial repair. TB-4's role in corneal, cardiac, and cutaneous wound healing has been characterized in preclinical models and a small number of Phase 2 human trials for dry-eye and pressure-ulcer indications.
GHK-Cu and copper-mediated repair
GHK-Cu is a naturally occurring copper tripeptide complex that drives collagen and glycosaminoglycan synthesis, modulates antioxidant defenses, and promotes wound remodeling. Originally characterized as a plasma factor, it is the most clinically studied recovery-adjacent peptide with dermatology and wound-care FDA cosmetic applications.
KPV and anti-inflammatory signaling
KPV is the C-terminal tripeptide of alpha-melanocyte stimulating hormone (α-MSH). It reduces inflammation in gut and skin models via downregulation of NF-κB signaling. Popular in DIY protocols for inflammatory bowel conditions, though human trial data are limited.
The complete list
7 peptides, ordered by clinical evidence tier. Each entry links to the full profile with mechanism, dosing, side effects, and legal-status detail.
BPC-157
Research (extensively studied)The category anchor. 15-amino-acid pentadecapeptide derived from human gastric juice with extensive preclinical evidence for tendon, ligament, muscle, and gut tissue repair. Not FDA-approved for any indication. The most popular self-experimental peptide in the biohacking community, widely used for joint injuries and connective-tissue repair despite limited human trial data.
TB-500
Research (synthetic TB-4 fragment)Synthetic fragment of thymosin beta-4. Promotes cell migration, angiogenesis, and wound healing in preclinical models. Commonly stacked with BPC-157 in the 'Wolverine stack' for musculoskeletal injury recovery. WADA-prohibited for athletes.
Thymosin Beta-4
Phase 2 (dry-eye, pressure ulcer)Full-length 43-amino-acid endogenous peptide and the parent molecule for TB-500. Phase 2 human trials for dry-eye disease and pressure-ulcer healing. Mechanism is cell migration, actin sequestration, and vascular endothelial repair.
Thymosin Beta-4 Sulfoxide
Research (oxidized isoform)Oxidized isoform of thymosin beta-4 generated at inflammation sites. Displays enhanced anti-inflammatory and monocyte migration-directing activity compared with the parent molecule. Preclinical only.
Fibronectin Peptides
ResearchShort peptide fragments derived from fibronectin, a major extracellular-matrix glycoprotein. Studied for wound healing and tissue regeneration by mimicking fibronectin's cell-adhesion and matrix-assembly functions.
GHK-Cu
Cosmetic-approved (skin crossover)Naturally occurring copper tripeptide (Gly-His-Lys plus Cu2+). Extensively studied for dermal wound healing, collagen synthesis, and anti-inflammatory effects. FDA-approved for cosmetic use; also used off-label for hair, scalp, and wound applications. Cross-listed from the Skin category because of its wound-healing evidence base.
KPV
Research (inflammation)C-terminal tripeptide of α-MSH (Lys-Pro-Val). Anti-inflammatory effects in gut and skin models via NF-κB downregulation. Used in DIY protocols for inflammatory bowel disease and inflammation-driven skin conditions. Cross-listed from the Immune category.
Compared at a glance
Recovery peptides differ from GLP-1s in a critical way: none of the seven on this hub is FDA-approved for the injury indications users commonly seek them for. Thymosin beta-4 is the most advanced in clinical trials (Phase 2). GHK-Cu has cosmetic FDA approval but not wound-care drug approval. BPC-157 and TB-500 — the most popular — have almost no human clinical-trial data despite decades of preclinical work. The table below shows where each compound sits on the evidence spectrum.
| Peptide | Mechanism | Primary use | FDA status | Route | Half-life |
|---|---|---|---|---|---|
| BPC-157 | GH receptor / FAK-paxillin | Tendon / gut / muscle | Research only | SC / oral | ~4 hours |
| TB-500 | G-actin sequestration | Musculoskeletal / vascular | Research only | SC / IM | ~2 hours |
| Thymosin Beta-4 | G-actin sequestration | Dry-eye / wound | Phase 2 | Ophthalmic / SC | ~2 hours |
| GHK-Cu | Copper / collagen | Skin / wound | Cosmetic approved | Topical / SC | ~5 hours |
| KPV | α-MSH / NF-κB | Gut / inflammation | Research only | Oral / rectal | ~1 hour |
BPC-157 and TB-500 dominate the recovery-peptide search volume despite having the weakest clinical-trial bases. Thymosin beta-4 and GHK-Cu have the strongest evidence bases but lower recognition. The disparity reflects the gap between internet popularity and regulatory reality: users searching for 'wolverine stack' are making an evidence-informed bet on preclinical data, not a prescription-grade clinical decision.
Safety, side effects & legal status
Recovery peptides are universally unapproved for injury repair and universally classified as research chemicals when purchased from gray-market vendors. Reported side effects are generally mild — injection-site reactions, transient nausea, occasional dizziness — but the safety database is thin because no recovery peptide has completed a large Phase 3 safety trial. The principal legal risk is not the peptide itself but the supply chain: BPC-157 in particular has been the subject of multiple FDA warning letters to compounders and suppliers since 2023. Athletes should note that TB-500 and thymosin beta-4 are explicitly listed on the WADA Prohibited List; BPC-157 is not currently listed but is covered by the S0 'Non-Approved Substances' category that prohibits any substance without current medical approval for human use. PeptaHub's legal-status review methodology is documented at /methodology.
How to think about this class
Recovery peptides occupy a particular place in the evidence hierarchy: strong preclinical data, thin clinical data, high user enthusiasm, and no regulatory path to indication-specific approval in sight. A user taking BPC-157 for a torn rotator cuff in 2026 is not making an evidence-based medical decision in the pharmaceutical sense — they are making a bet that the rat and rabbit tendon-injury models will translate to humans. That bet may pay off (the preclinical data are genuinely strong) or may not (clinical translation of tissue-repair drugs has a poor historical track record). The rational approach is clinician-supervised use of FDA-approved alternatives when they exist, honest discussion of uncertainty when they don't, and conservative stacking — not 'BPC-157 + TB-500 + GHK-Cu + KPV everything' but targeted single-peptide protocols aligned to the specific injury and the strongest available evidence.
Frequently asked questions
BPC-157 is a 15-amino-acid peptide derived from human gastric juice that primarily works by upregulating growth hormone receptors in tendon fibroblasts and promoting angiogenesis. TB-500 is a synthetic fragment of thymosin beta-4 that works by sequestering G-actin and driving cell migration and vascular repair. They target different mechanisms, which is why the 'Wolverine stack' uses both together — the idea is that BPC-157 accelerates local tissue repair while TB-500 enhances blood-flow and cell migration to the injury site. Neither has been compared head-to-head in a human trial, so the stacking rationale is mechanistic rather than empirical.
Not in humans. The 'Wolverine stack' (BPC-157 + TB-500, sometimes with GHK-Cu or growth hormone analogs added) is backed by strong preclinical data — rat tendon-injury models, rabbit Achilles-tendon studies, and muscle-regeneration assays — but almost no randomized human trials. A systematic review published in 2025 identified only a handful of small human case series with BPC-157 and none for the specific stack combination. The reputation comes from community self-reports and bodybuilding forums, not controlled trials.
No recovery peptide is FDA-approved for the injury indications users commonly seek them for (tendon tears, ligament sprains, muscle injury, joint repair). Thymosin beta-4 is in Phase 2 trials for dry-eye disease and pressure-ulcer healing — the most advanced clinical development of any recovery peptide — but has not received approval. GHK-Cu is FDA-approved for cosmetic topical use but not as a drug for wound care. BPC-157 and TB-500 are classified as research chemicals in the US and are not legal to sell as human medications.
User reports typically describe subjective improvement within 1–3 weeks of initiating BPC-157 for connective-tissue injuries, with continued improvement over 4–8 weeks. Preclinical tendon-injury studies show accelerated histological healing within 14 days compared with controls. The variance is wide, and the absence of human trial data means typical timelines are anecdotal. Injuries with poor blood supply (deep tendon, cartilage) may respond more slowly than well-vascularized tissues (muscle, gut mucosa).
Tendon and ligament repair is where BPC-157's preclinical evidence is strongest. Multiple rat Achilles-tendon transection studies show accelerated healing, improved biomechanical strength, and better cellular organization at 14-day follow-up compared with saline controls. Whether that translates to humans with partial tendon tears, tendinopathy, or ligament sprains is the open question. The 2025 systematic review in Orthopaedic Sports Medicine found limited but suggestive human case-series data supporting BPC-157 for musculoskeletal indications but emphasized the need for randomized trials.
Thymosin beta-4 is explicitly listed on the WADA Prohibited List under S2 (growth factors). TB-500, as a TB-4 fragment, is covered by the same listing. BPC-157 is not explicitly named but falls under the S0 'Non-Approved Substances' category that prohibits any substance lacking current medical approval for human use. Athletes subject to WADA, USADA, or collegiate/professional sports drug-testing protocols should assume all recovery peptides are prohibited unless explicitly cleared by their governing body.
The principal risks are supply-chain contamination (peptides sold as 'research-only' bypass pharmaceutical sterility and purity standards), injection-site infection, unquantified long-term effects (no recovery peptide has 10+ year safety data in humans), and legal/athletic exposure if subject to drug testing. The peptides themselves have favorable acute toxicity profiles in preclinical data, but 'favorable preclinical toxicity' is not the same as 'established human safety.' Users choosing to self-experiment should source from suppliers with published third-party testing, use aseptic injection technique, monitor for unusual symptoms, and discuss the decision with a clinician familiar with the literature.
Sources & further reading
External citations underpinning this page. PeptaHub's full sourcing methodology is documented at /methodology — every claim on this page traces back to one of these references or a linked profile.
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — PMC
- BPC-157 Human Clinical Trials (2025–2026) — Peptide Database
- Thymosin Beta-4 wound healing mechanisms — literature search — PubMed
- Prohibited List — WADA
- Compounding Warning Letters — BPC-157 enforcement posture — FDA
See also: glossary, FAQ, about PeptaHub.